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Abstract
Background Patient knowledge about chronic diseases
increases health-promoting behaviors and improves clinical
outcomes. We assessed this association for patients with
chronic viral hepatitis.
Methods Untreated patients chronically infected with HBV
(n = 500) or HCV (n = 500) were enrolled at 19 centers
across India. A survey, adapted from the US CDC National
Health and Nutrition Examination Survey (NHANES)
questionnaire, was administered at a single visit to assess
HBV/HCV knowledge, community disease awareness,
treatment quality, and healthcare barriers. We developed
the India Hepatitis Knowledge Index (IHKI), where a
higher IHKI score (range 0–10) indicates increased
hepatitis knowledge. Multivariate regression models eval-
uated demographic and disease factors.
Results The overall mean IHKI score was 5.6 out of 10,
with higher scores among patients with HBV (5.9) than
HCV (5.3); p\ 0.001. In HBV patients lower IHKI was
associated with shorter disease duration, government clinic
attendance (p\ 0.0001), fewer personal experiences with
HBV (p\ 0.0001), and residing in northern India. Among
HCV patients, lower IHKI was associated with shorter
disease duration, community (p\ 0.0001) and government
clinic attendance (p\ 0.0001), and fewer personal expe-
riences with HCV (p\ 0.0001). Among HBV patients,
IHKI was independently associated with disease severity as
assessed by MELD score, albumin, and APRI. This asso-
ciation was strongest for HBV patients with elevated ALT
and HBV DNA[2000 IU/ml. Among HCV patients, IHKI
results had no significant associations with disease severity.
Conclusions The association of IHKI with disease under-
scores the need to understand connections between hep-
atitis knowledge and progression and may guide efforts to
address patient education and awareness of chronic viral
hepatitis in India.
Keywords Hepatitis B virus  Hepatitis C virus  Disease
knowledge  India
Background
HBV and HCV infections continue to be global health
concerns, affecting over 500 million people worldwide [1].
India remains a country with a high burden of viral hep-
atitis. It is estimated that the prevalence of HCV
is *0.5–1.0 % and *2–8 % for HBV [2–6]. While
infection rates are high, engagement with the healthcare
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system is limited in part by access to healthcare systems
and individual knowledge of disease transmission, natural
history, and treatment options [7, 8]. With the availability
of a preventative vaccine for HBV and effective therapies
for HBV and HCV, improving interactions with healthcare
systems may improve overall health for those infected with
HBV and HCV.
Hepatitis knowledge has been demonstrated to be
associated with disease management and outcomes, with
improved management and outcomes among those with
increased knowledge of the disease [8, 9]. Further, as
knowledge of transmission improves, rates of disease
screening and incidence have been shown to decrease [10].
There is a lack of data, however, assessing the overall
knowledge of disease for viral hepatitis and evaluating
associations with clinical parameters. Assessing the current
status of disease knowledge is important for demonstrating
knowledge gaps that ultimately will be useful for designing
specific public health interventions.
In this study, we assess disease knowledge of HBV and
HCV in India using a series of questions administered to 500
HBV and 500 HCV patients throughout India. The goals of
this study are to (1) characterize and validate answers to a
series of questions adapted from the NHANES question-
naire, (2) identify differences in knowledge awareness of
disease between HBV- and HCV-infected patients, and (3)
identify associations with clinical parameters.
Methods
Study population
A total of 500 HBV and 500 HCV patients were recruited
from 19 centers geographically distributed across India.
Practice types included community clinics, government
hospitals, government assistance programs, and private
practices. At a single study visit, a survey was administered
and clinical laboratory tests were performed. The surveys
collected information on participants’ sociodemographic
characteristics, hepatitis-related knowledge, experiences,
and behaviors and were subsequently linked to partici-
pants’ laboratory and clinical measures. This study was
approved by the Institutional Review Boards governing the
participating centers.
Description of study variables
India Hepatitis Knowledge Index
We used ten hepatitis survey questions adapted from the
NHANES follow-up questionnaire for hepatitis C to create
the India Hepatitis Knowledge Index (IHKI) [11]. These
ten questions assessed patient knowledge of hepatitis dis-
ease transmission, natural history, treatment, and preven-
tion options. HBV and HCV patients were only asked
about knowledge regarding their specific hepatitis type.
We conducted a factor analysis by hepatitis type to
assess whether items on the knowledge scale hold together
as one or more constructs or measures of knowledge. Only
one distinct factor of knowledge was identified in factor
analysis. For each hepatitis type, a Cronbach’s alpha (a) for
the reliability of our ten scale items to assess the adequacy
of scale reliability was performed. We created IHKI by
hepatitis B or C patients. The index score was the number
of correct questions (index range 0–10).
Clinical laboratory tests/values
At the clinic visit, clinical laboratory assessments were made
including AST, ALT, albumin, bilirubin (total and direct),
INR for prothrombin time, GGT, and creatinine. Viral fac-
tors evaluated were HCV RNA and HCV genotyping (for
those with HCV infection) and HBV DNA, HBeAg, and anti-
HBeAg (for those with HBV infection). MELD and APRI
calculations were performed for all patients.
For sensitivity analyses, we categorized patients into
high ALT or low ALT using separate cutoffs for males and
females. For males, high ALT was defined as ALT C90
and low ALT was defined as ALT\90; for females, high
ALT was defined as ALT C57 and low ALT was defined
as ALT\57. We also categorized HBV patients into high
and low viral counts (high viral load C2000 IU/ml, low
viral load\2000 IU/ml).
Covariates
We included age, sex, duration of infection, type of
healthcare practice, geographic region of India, and hep-
atitis experience as covariates in the analysis. All covari-
ates were collected from the patient survey. Age was
measured continuously. Duration of hepatitis was defined
as\1 year, 2–5 years, and[5 years. Patients were asked
at what type of healthcare practice they received most of
their regular care (private practice, community clinic,
government hospital/program). The location of participat-
ing centers was classified into four distinct regions of India
(i.e., north, south, west, and east).
A summary measure of personal experiences with hep-
atitis was calculated from three survey questions and used
to capture previous exposure to hepatitis as a possible
predictor of knowledge and clinical outcomes. Personal
experience with hepatitis was calculated from questions
asking whether the respondent had family members with
hepatitis, whether a family member had died from
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hepatitis, and whether the respondent lived in a community
that spoke openly about hepatitis (yes/no). One point was
given for every question where the patient answered yes
(response range 0–3). The options ‘‘refused to answer’’ and
‘‘don’t know’’ were available for all survey questions.
Statistical analysis
We assessed associations of hepatitis type, clinical values,
and knowledge scores by patient sociodemographic factors
using chi-square tests and one-way analysis of variance
tests appropriate for our categorical and continuous mea-
sures of variables, respectively. We used Pearson correla-
tions to examine associations between continuous
sociodemographic characteristics and knowledge scores
and median regression to examine associations between
laboratory medians and sociodemographic characteristics.
Linear and logistic regressions were used to examine
adjusted associations between sociodemographic charac-
teristics and knowledge scores and between knowledge
scores and clinical outcomes measured continuously and
categorically. Age was centered in our models. Multivari-
ate models for knowledge included age, sex, duration of
infection, healthcare clinic type, and personal experience
with hepatitis. Models for clinical outcomes included the
hepatitis knowledge score.
In our sensitivity analysis we assessed how associations
between knowledge and clinical outcomes varied for
individuals with low and high ALT and for HBV patients
with low and high levels of HBV DNA. All analyses were
performed using STATA/SE 13.1.
Results
Among our sample of 1000 respondents, 1 (\0.1 %) person
had missing values for the knowledge score and was
excluded from the analysis. In the analytic sample, overall
the mean (SD) age was 41 (13) years, 72 % were male, and
75 % were Hindu, 6 % Muslim, 8 % Sikh, 9 % Christian,
and 1 % some other religion (Table 1). Over half of
respondents reported hepatitis duration of less than 1 year,
28 % reported 2–5 years, 10 % reported having duration of
more than 5 years, and 12 % refused to answer or did not
know their duration of infection. Most respondents
received primary care at private practices (61 %), com-
munity clinics (7 %), and government program (28 %), and
12 % refused to report or did not know the type of practice
where they received care. Comparing HBV and HCV
patients, those with HCV tended to be older (45 versus
37 years), more were females (34.4 versus 21.4 %), and
more HBV patients reported a family history of hepatitis
(24 versus 14 %). For both HBV and HCV patients the
majority of patients had elevated ALT levels. Compared to
HBV patients the HCV patients had laboratory values
consistent with active or more advanced disease, including
ALT (73 versus 50 U/l), albumin (3.8 versus 4.3 g/dl), and
APRI (1.4 versus 0.4).
Correct responses to the ten knowledge questions are
shown in Table 2. Correct responses to questions ranged
from 35 to 73 % for patients with HBV and 32–78 % for
HCV. For most questions, there were no statistically sig-
nificant differences in correct responses according to HBV
versus HCV infection. Notably there were two questions
regarding transmission (i.e., if sex with an infected partner
is a risk factor for infection or whether hepatitis can be
transmitted from mother to child through birth) and one
question concerning the availability of a vaccine (all
p\ 0.0001) in which more HBV patients answered the
questions correctly. We summed the number of correctly
answered knowledge questions to create a knowledge
index. For each hepatitis type (i.e., HBV versus HCV), we
found the adequacy of index reliability (HBV: a = 0.81;
HCV a = 0.75), and the validity of the constructed
knowledge composite score was determined by performing
a factor analysis to identify the number of underlying
factors measured by the knowledge questions. For both
HBV and HCV, this analysis demonstrated a one-factor
solution for both HBV and HCV patients (Supplemental
table 1). We also evaluated the internal consistency of the
index using Cronbach’s alpha, which demonstrated a high
index of reliability (HBV: a = 0.81; HCV a = 0.75). The
IHKI score was set as the number of correct questions
answered by an individual. The overall mean IHKI score
for the entire population was 5.6 out of 10 (SD 2.8).
Overall, HBV patients had higher knowledge scores than
HCV patients (HBV scores 5.9 than HCV scores 5.3;
p\ 0.001). Questions that appeared to contribute the most
to differences in knowledge were those associated with
transmission and vaccination.
The average knowledge scores by sociodemographic
characteristics are shown in Table 3. Males and females
with HBV had similar knowledge scores; however, for
HCV, females had lower knowledge scores than males.
Overall, respondents with a longer duration of infection
and more personal family or community awareness of
hepatitis had higher knowledge scores. In the overall
population and for the HBV and HCV groups, there was a
trend toward increased knowledge with a longer duration
of infection, attending private practice, a family history of
hepatitis and hepatitis-related death, and community
awareness of disease. While not a predictor for either HBV
or HCV, the overall group of patients showed a weak trend
toward increased knowledge with lower age. Groups that





Sociodemographic characteristics Hepatitis type
Total study sample HBV HCV p values*
All sample 999 499 500
Mean age in years (SD) 41 (13) 37 (12) 45 (13) \0.001
Sex
Female 278 (28 %) 106 (21 %) 172 (34 %) \0.001
Male 721 (72 %) 393 (79 %) 328 (66 %)
Religion
Hindu 754 (75 %) 405 (81 %) 349 (70 %) \0.001
Muslim 64 (6 %) 38 (8 %) 26 (5 %)
Sikh 81 (8 %) 24 (5 %) 57 (11 %)
Christian 93 (9 %) 28 (6 %) 65 (13 %)
Other 7 (1 %) 4 (1 %) 3 (1 %)
Duration of hepatitisa
Less than 1 year 505 (51 %) 259 (52 %) 246 (49 %) 0.365
2–5 years 275 (28 %) 125 (25 %) 150 (30 %)
[5 years 100 (10 %) 53 (11 %) 47 (9 %)
Refused/do not know 119 (12 %) 62 (12 %) 57 (11 %)
Healthcare practice type
Private practice 606 (61 %) 303 (61 %) 303 (61 %) 0.686
Community clinic 72 (7 %) 36 (7 %) 36 (7 %)
Government program 282 (28 %) 137 (27 %) 145 (29 %)
Refused/DK 39 (4 %) 23 (5 %) 16 (3 %)
Geographic region of India
North 250 (25 %) 125 (25 %) 125 (25 %) 1.000
South 249 (25 %) 124 (25 %) 125 (25 %)
West 250 (25 %) 125 (25 %) 125 (25 %)
East 250 (25 %) 125 (25 %) 125 (25 %)
Family history of hepatitisa
Yes 194 (19 %) 122 (24 %) 72 (14 %) \0.001
No/Ref/DK 805 (81 %) 377 (76 %) 428 (86 %)
Family death due to hepatitisa
Yes 82 (8 %) 49 (10 %) 33 (7 %) 0.064
No/Ref/DK 917 (92 %) 450 (90 %) 467 (93 %)
Community awareness of hepatitisa
Yes 303 (30 %) 147 (29 %) 156 (31 %) 0.549
No/Ref/DK 696 (70 %) 352 (71 %) 344 (69 %)
Clinical laboratory values, median (IQR)
ALT, U/l 50 (39–72) 73 (50–112) \0.001
Albumin, g/dl 4.3 (3.9–4.5) 3.8 (3.2–4.3) \0.001
Total bilirubin, g/dl 0.6 (0.4–1.0) 0.8 (0.5–1.3) \0.001
Direct bilirubin, mg/dl 0.1 (0.1–0.2) 0.2 (0.1–0.5) \0.001
APRI 0.4 (0.3–1.0) 1.4 (0.6–3.1) \0.001
MELD 7 (6–9) 8 (7–11) \0.001
* p values were calculated using chi-square tests of association for categorical sociodemographic char-
acteristics and analysis of variance for continuous sociodemographic characteristics
a For HBV respondents, questions were asked in reference to HBV; for HCV respondents, questions were
asked in reference to HCV
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performed the highest in the overall knowledge score
included HBV patients with[5 years of disease duration
and HBV patients with a family death due to hepatitis.
Multivariate analysis did not show age or gender to be
associated with knowledge scores for hepatitis B or C
(Table 4). For both HBV and HCV the duration of dis-
ease, type of healthcare practice, geographic regions in
India, and personal experience with hepatitis were all
associated with the mean knowledge score. Longer
duration of infection, 2–5 years (for HBV, coefficient: 1.0
CI: 0.42, 1.6 and for HCV, coefficient: 0.8 CI: 0.28, 1.31)
or more than 5 years (for HBV, coefficient: 1.1 CI: 0.29,
1.92 and for HCV, coefficient: 1.0 CI: 0.22, 1.79), was
related to higher mean knowledge scores compared to
respondents with less than 1 year since the time of
diagnosis. Attending a community clinic (for HCV,
coefficient: -1.43 CI: -2.32, -0.53) and government
clinics (for HBV, coefficient: -0.085 CI: -1.44, -0.27
and for HCV, coefficient: -0.84 CI: -1.38, -0.31) was
also associated with lower mean knowledge scores com-
pared to those attending private practices. Increased per-
sonal experiences with hepatitis also were positively
associated with increases in the knowledge score, and
every additional experience with disease (0–3) increased
the knowledge score by 0.82 (CI 0.51, 1.13). In adjusted
models, patients who refused to answer or did not know
the duration of infection or type of primary care clinic
had the lowest knowledge scores compared to those
with\1 year disease duration and those visiting private
practice clinics.
Association with clinical parameters
In adjusted analysis, we found that increased knowledge
was related to better clinical outcomes for hepatitis B
patients (Table 5). An increase in the IHKI score was
related to lower MELD and APRI scores and lower INR,
and bilirubin (total and direct) while associated with higher
albumin levels. For patients with hepatitis C, no significant
associations were seen although a trend toward lower
MELD and higher albumin was seen with improved
knowledge. In sensitivity analysis, we found the associa-
tions for hepatitis B to be strengthened for high HBV DNA
and elevated ALT, a subgroup of hepatitis B patients who
may have increased liver damage or more advanced liver
disease (Supplemental table 2).
Conclusions
In conclusion, our study demonstrates that a reliable scale
of knowledge can be created using a simple survey that can
be administered across diverse regions in India. Our results
show that patients with HBV tend to have higher awareness
of their disease and specifically have increased knowledge
about modes of transmission and the availability of a
vaccine as compared with patients with HCV. As might be
expected, factors related to improved disease awareness
included longer duration of infection and personal experi-
ence with hepatitis such as a family history of or family
death from hepatitis. We did note that there was a trend
Table 2 Hepatitis virus knowledge scale results









Can hepatitis B/C patients transmit the disease to others? 295 (59 %) 267 (53 %) 0.069
Is having sex with someone who suffers from hepatitis B/C a risk factor for getting infected with
hepatitis B/C?
268 (54 %) 209 (42 %) \0.001
You can get hepatitis B/C by being born to a mother who suffers from hepatitis B/C when she
gave birth
252 (51 %) 187 (37 %) \0.001
You can get hepatitis B/C by being pricked with a needle or sharp instrument or injecting illegal
drugs with a needle that has hepatitis B/C-infected blood on it
351 (70 %) 362 (72 %) 0.472
You can get hepatitis B/C by receiving a blood transfusion from a hepatitis B/C-infected donor 365 (73 %) 389 (78 %) 0.087
If someone is infected with hepatitis B/C virus they will most probably carry the virus all their
lives
176 (35 %) 172 (34 %) 0.773
Infection with the hepatitis B/C virus can cause the liver to stop functioning 252 (51 %) 250 (50 %) 0.874
Someone suffering from hepatitis B/C can look and feel fine 307 (62 %) 305 (61 %) 0.865
Is hepatitis B/C a treatable disease? 345 (69 %) 352 (70 %) 0.664
Is there a vaccine available for hepatitis B/C? 351 (70 %) 162 (32 %) \0.001
* p values were calculated using chi-square tests of association
a For HBV respondents, questions were asked in reference to HBV; for HCV respondents, questions were asked in reference to HCV
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toward an association of lower age and improved knowl-
edge for the overall population, which may reflect an
increase in knowledge in younger populations as a result of
improved access to information. Of note, in the overall
population religion, gender, and region of India were not
associated with the knowledge score on univariate analysis.
Finally, receiving care in a private practice setting was
associated with higher knowledge scores for both HBV and
HCV, which may be tied to socioeconomic status (SES).
As SES was not assessed in this study, the reason for these
improved scores among patients being seen in private
practice cannot be definitively assessed.
Somewhat surprisingly, even with a limited set of
questions evaluating knowledge, an association was seen
Table 3 Sociodemographic characteristic and hepatitis knowledge score
Sociodemographic characteristics Overall knowledge score p value Hepatitis type
HBV knowledge score p value HCV knowledge score p value
All sample 999 499 500
Age (correlation) -0.08 0.009 -0.06 0.217 0.2166 0.321
Sex
Female 5.4 0.060 6.0 0.916 5.0 0.044
Male 5.7 6.0 5.5
Religion
Hindu 5.7 0.119 6.0 0.1660 5.2 0.13
Muslim 5.1 5.5 4.5
Sikh 5.1 4.6 5.4
Christian 6.0 6.2 5.9
Other 6.4 6.3 6.7
Duration of hepatitisa
Less than 1 year 5.4 \0.001 5.7 \0.001 5.1 \0.001
2–5 years 6.2 6.6 5.9
[5 years 6.6 7 6.0
Refused/DK 4.3 4.4 4.1
Healthcare practice type
Private practice 6.1 \0.001 6.4 \0.001 5.7 \0.001
Community clinic 5.0 5.6 4.4
Government program 5.0 5.3 4.8
Refused/missing 4.1 4.2 3.9
Geographic region of India
North 5.5 0.516 5.6 0.178 5.4 0.012
South 5.8 6.1 5.4
West 5.5 6.3 4.7
East 5.7 5.7 5.7
Family history of hepatitisa
Yes 6.5 \0.001 6.9 \0.001 6.0 0.018
No/Ref/DK 5.4 5.6 5.2
Family death due to hepatitisa
Yes 6.7 \0.001 7.0 \0.001 6.2 0.035
No/Ref/DK 5.5 5.8 5.2
Community awareness of hepatitisa
Yes 6.2 \0.001 6.7 \0.001 5.8 \0.001
No/Ref/DK 5.4 5.6 5.1
* p values were calculated using analysis of variance for categorical sociodemographic characteristics and Pearson correlations for continuous
variables
a For HBV respondents, questions were asked in reference to HBV; for HCV respondents, questions were asked in reference to HCV
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with important clinical parameters including MELD,
APRI, albumin, and bilirubin for HBV patients. This
association may be interpreted to mean that individuals
with lower knowledge about HBV tend to present in
healthcare settings later and with more advanced disease.
This is strengthened by the finding of an augmented effect
Table 4 Multivariate regression for predictors of knowledge scores
Factors HBV HCV
b SE p value LCI UCI b SE p value LCI UCI
Age -0.01 0.01 0.21 -0.03 0.01 -0.02 0.01 0.10 -0.03 0.00
Sex
Male REF REF
Female -0.07 0.30 0.82 -0.66 0.52 -0.46 0.24 0.06 -0.93 0.01
Duration of hepatitisa
Less than 1 year REF REF
2–5 years 1.01 0.30 0.00 0.42 1.60 0.80 0.26 0.00 0.28 1.31
[5 years 1.10 0.41 0.01 0.29 1.92 1.00 0.40 0.01 0.22 1.79
Refused/DK -0.90 0.40 0.02 -1.68 -0.12 -0.83 0.37 0.02 -1.55 -0.11
Healthcare practice type
Private practice REF REF
Community clinic -0.42 0.49 0.39 -1.38 0.54 -1.43 0.46 0.00 -2.32 -0.53
Government program -0.85 0.30 0.00 -1.44 -0.27 -0.84 0.27 0.00 -1.38 -0.31
Refused/missing -1.76 0.59 0.00 -2.92 -0.60 -1.60 0.64 0.01 -2.85 -0.35
Geographic region of India
North REF REF
South 0.58 0.36 0.11 -0.13 1.29 0.15 0.35 0.67 -0.53 0.83
West 0.69 0.35 0.05 0.00 1.39 -0.62 0.34 0.06 -1.28 0.03
East 0.18 0.36 0.63 -0.53 0.88 0.39 0.33 0.24 -0.26 1.04
Personal experiences with hepatitisa,b 0.82 0.16 0.00 0.51 1.13 0.54 0.16 0.00 0.22 0.86
_Cons 5.10 0.35 0.00 4.42 5.79 5.43 0.34 0.00 4.77 6.09
a For HBV respondents, questions were asked in reference to HBV; for HCV respondents, questions were asked in reference to HCV
b Personal experiences were derived from questions asking if the respondent had family members with hepatitis, if any family member had died
from hepatitis, and whether they lived in a community that spoke about hepatitis (yes/no). One point was given for every question where the
patient answered yes (response range: 0–3)
Table 5 Associations from adjusted linear or logistic regression of hepatitis knowledge and clinical outcomes by hepatitis type
Continuous clinical outcomes HBV HCV
b SE p value LCI UCI b SE p value LCI UCI
MELD -0.21 0.06 0.00 -0.33 -0.08 -0.16 0.09 0.08 -0.33 0.02
Albumin 0.02 0.01 0.01 0.01 0.04 0.02 0.01 0.07 0.00 0.04
PT/INR -0.01 0.01 0.01 -0.02 0.00 0.00 0.00 0.87 -0.01 0.01
Total bilirubin -0.21 0.06 0.00 -0.33 -0.08 -0.01 0.03 0.75 -0.07 0.05
Direct bilirubin -0.13 0.04 0.00 -0.22 -0.05 -0.01 0.02 0.64 -0.04 0.02
ALT -3.58 3.91 0.36 -11.25 4.09 1.91 1.25 0.13 -0.54 4.36
Dichotomized clinical outcomes HBV HCV
OR SE p value LCI UCI OR SE p value LCI UCI
APRI 0.84 0.04 0.00 0.76 0.93 1.01 0.04 0.87 0.93 1.09
High ALT 0.95 0.04 0.20 0.87 1.03 1.01 0.04 0.84 0.94 1.09
Models adjusted for age, sex, healthcare practice type, region of India, and personal experiences with hepatitis
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among HBV patients with elevated ALT and HBV DNA.
Given this is a single-visit, cross-sectional study, causality
cannot be determined. These associations were more
apparent for HBV, whereas only trends were noted for
HCV. The reason for the lack of statistical significance
among HCV patients may reflect higher values and vari-
ability in clinical laboratory results among HCV patients
due to more advanced liver disease than in HBV patients or
due to differences in sociodemographic predictors for
contracting HCV versus HBV infection.
Despite the relatively large sample size and broad geo-
graphic distribution of the survey, there are several limi-
tations of this study. While multiple centers were used for
the study, sites were chosen based on feasibility rather than
on a population-based sample, thereby limiting the gener-
alizability of the findings to India and other populations.
While broad concepts could be assessed with this simple
survey, we were unable to evaluate more subtle differences
in knowledge with only ten questions. This survey was also
performed in conjunction with a blood draw, which may
also introduce selection bias among patients being seen at
these clinics. Finally, we did not collect the SES and
educational levels of patients in our study, which may be
important possible confounders for the results observed.
While SES may be inferred from the practice type in which
patients were seen, no definitive assessment of either SES
or education was known, and no additional analysis was
possible.
The findings of this survey demonstrate the overall low
level of knowledge of basic disease transmission and nat-
ural history among patients in India and highlights the need
for further education concerning HBV and HCV. Further,
that lower disease knowledge may be associated with more
advanced disease at the time of presentation may imply a
tangible benefit of improved education among the popu-
lation. With effective preventative and therapeutic options
for HBV and HCV infection, improving disease knowledge
may impact the overall disease burden in India.
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